The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors
about
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle releaseHIV type 1 Gag as a target for antiviral therapyVirus maturation as a new HIV-1 therapeutic targetIdentification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipidsDifferential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartmentsDifferential membrane binding of the human immunodeficiency virus type 1 matrix proteinProcessing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.Pharmacological intervention of HIV-1 maturationAlkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNAInhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitorsReplication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acidGeneration and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitorSecond locus involved in human immunodeficiency virus type 1 resistance to protease inhibitorsStructure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396A possible homology between immunodeficiency virus p24 core protein and picornaviral VP2 coat protein: prediction of HIV p24 antigenic sites.Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase.Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusionMolecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral proteaseNovel approaches to inhibiting HIV-1 replication.Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells by biarsenical labeling.Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain.A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assemblyCryoelectron microscopic examination of human immunodeficiency virus type 1 virions with mutations in the cyclophilin A binding loop.Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release.The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly.Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly.Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domainHuman immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cellsHuman immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimatPhosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis.Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequencesCalmodulin disrupts the structure of the HIV-1 MA proteinThe late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner
P2860
Q24559906-1050FAD3-80B5-461B-AF01-AF976566C6F6Q24563651-6450D017-8DFA-4F33-929B-375D58D31AF1Q24614498-E9AD3098-3408-44DC-BF6B-9A0123F446FBQ24642446-4959BC99-1C08-4817-85A3-9B108E0D23C5Q24646680-B8F2208B-3960-414E-AFC0-9C95BE9B85F1Q24646897-1221AE59-8B5F-4D46-90B4-543D4CEB5FD6Q24679629-4FF768A8-0BB4-4C7E-A244-A68386F38C08Q24812175-B2AFD00A-DB28-4446-AAC1-FDE47080635AQ26771739-D0D936A2-3F51-47F4-AFC1-DC0928A6ED78Q27324263-10ECF735-C1B6-4D96-A201-457030157AFBQ28272788-62709EFA-B7EF-4A48-95CD-59F53EA7E0B1Q28355570-5D602CD6-95A8-426B-9C98-AA30E2F8E7F3Q28359721-61826D59-1F1B-4172-8E10-B490D7198CEDQ28378387-3719A189-181E-40F2-BDBB-C44E899DC7FDQ28378860-6F21BEC2-3790-4D72-A8F2-0D42772B44C5Q28828191-1C9C15A9-42DC-455F-8E85-895AD9648BE9Q30196021-3ABA0170-283B-47A2-A66B-380D28A89F34Q30423782-3670E4E7-A6DA-4E79-8827-7C411B666B2BQ30452154-BC65FA6B-988C-4AC5-8E0D-B3085168DBE1Q30505286-4464F705-8311-4811-B1C8-B877790D7D3CQ30708352-6C98A3B3-A54B-49D9-A3BF-2029B32B332AQ30850215-17156FBA-E691-4A80-A548-F444F81B7E24Q33624690-8316614F-C1FC-4AD2-A75F-7EA867C41F0FQ33685950-90B87044-933F-44D9-B74E-1BAA8632846EQ33707507-9112E2C1-B62D-4C37-A1D8-8C0F0C12E809Q33781019-4DFCC4B9-ABE0-4661-8363-A18C63CA25FBQ33782263-F0163762-321A-408F-B265-1711C3A9E2DEQ33782377-5C252718-0AC3-4CF3-A684-F655EC8E584DQ33782886-88FEE3EE-479E-40C2-B471-5126C99EDEE6Q33784754-43DDE69B-D1A8-40A7-8E52-F9EAD0710028Q33785479-995F52DF-D961-4412-AD8E-A92579FBFEC4Q33794223-A4F59A6F-2881-45A0-B48A-BCECBB9E157BQ33801779-B45C9FE8-EC7F-4228-81E0-3FB18A89D143Q33811857-D944BB15-1335-486C-9382-E01EBEDF85F4Q33845811-0E14A4A7-9587-4F41-BEAD-4867070FC06EQ33864444-56286F20-9B55-4CE3-91DE-694BAE488FF9Q33880794-F0B58A92-276D-46EE-9BA8-2CD2DFBB3694Q33930053-E282004B-8917-4D70-8F9C-E00D3078554AQ33987311-0247110F-0ADD-4A3B-9AF3-B9B9A7C96A31Q34104639-66864598-8BFE-4AB8-AD06-E689E083675F
P2860
The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
The gag gene products of human ...... for alternative gag precursors
@en
type
label
The gag gene products of human ...... for alternative gag precursors
@en
prefLabel
The gag gene products of human ...... for alternative gag precursors
@en
P2093
P2860
P1433
P1476
The gag gene products of human ...... for alternative gag precursors
@en
P2093
Lillehoj EP
Salazar FH
Venkatesan S
P2860
P304
P407
P577
1988-11-01T00:00:00Z